Best Research Reports for Salesforce, Shopify, and AstraZeneca
Tuesday, June 15, 2021
Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including salesforce.com (CRM), Shopify (SHOP) and AstraZeneca (AZN). These research reports were handpicked from the roughly 70 reports released by our team of analysts today.
You can see all today’s research reports here >>>
Actions of Selling power underperformed Zacks’ IT software industry over the cumulative period (+ 10.7% vs. + 15.9%), but the Zacks analyst considers the company to be well positioned to benefit from a robust demand environment as customers undergo transformation.
Additionally, Slack’s recent acquisition agreement would position the company as a leader in the enterprise team collaboration solutions space and better compete with Microsoft’s Teams product. However, unfavorable currency fluctuations along with increasing investments in international expansions and data centers constitute a short-term profit surplus.
(You can read the full salesforce research report here >>>)
Shopify stocks have gained + 14.3% in the past six months against Zacks’ internet services industry gain of + 27.2%, reflecting market skepticism about the company’s outlook in the post world -pandemic.
A slight increase in Shopify Shipping, Shopify Payments, and Shopify Capital has consistently pushed up revenue. Additionally, partnerships with TikTok, Walmart, and Facebook are likely to expand the merchant base. However, higher investments in product development amid fierce competition in e-commerce will limit margin expansion in the short term.
(You can read the full Shopify research report here >>>)
Actions of AstraZeneca have gained + 17.2% in the last three months against the gain of + 9.7% of the pharmaceutical industry of Zacks Large Cap. The Zacks analyst believes that AstraZeneca products like Nexium and Seroquel face generic competition, which weighs on its sales.
However, new drugs such as Tagrisso and Imfinzi are expected to continue to generate revenue. The company also has a strong pipeline with a series of Phase III data readings scheduled for the current year. It has also engaged in external acquisitions and strategic collaborations to strengthen its pipeline while investing in high growth geographic areas such as China.
(You can read the full research report on AstraZeneca here >>>)
Other notable reports we present today include Prologis (PLD), Micron Technology (UM) and Ecolab (ECL).
Zacks names the “best single pick to double”
Among thousands of stocks, 5 Zacks experts each chose their favorite to skyrocket + 100% or more in the coming months. Of these 5, research director Sheraz Mian chooses one to have the most explosive advantage of all.
You’ve known this company from its past glory days, but few would expect it to be ready for a monster turnaround. Fresh out of a successful repositioning and flush with top celebrity mentions, it could rival or overtake other recent Zacks stocks which are expected to double as Boston Beer Company which climbed + 143.0% in just over 9 months and Nvidia which climbed + 175.9% in a year.
Free: see our best stock and 4 finalists >>
Note: Sheraz Mian heads Zacks’ equity research department and is a renowned expert on aggregate earnings. He is frequently cited in the print and electronic media and publishes the weekly Income trends and Income overview reports. If you would like to receive an email notification every time Sheraz publishes a new article, please click here >>>
To read of the day
Support for digital transformation and Salesforce acquisitions (CRM)
Product Deployments and Merchant Base Growth Shopify Help (SHOP)
Cancer drugs drive sales of strong pipeline AstraZeneca (AZN)
Adoption of e-commerce, high inventory to help Prologis (PLD)
According to the Zacks analyst, the rapid adoption of e-commerce and higher inventory levels are expected to drive demand for Prologis assets.
Micron (MU) Benefits from Growing Demand for Memory Chips
According to Zacks analyst, Micron is growing on strong demand for memory chips from PC makers and data center operators as the COVID-19 pandemic has spurred the trend towards work and work. home learning.
Global Healthcare and Life Sciences Unit Aids Ecolab (ECL)
According to Zacks analyst, the strength of the main segment of global health and life sciences due to coronavirus-related demand in these lines of business is helping Ecolab.
Business restructuring, MetLife (MET) strong balance sheet support
According to the Zacks analyst, the separation of many low-performing businesses and the acquisition of targeted businesses allowed the focus to be on key areas; its solid capital position favors strategic investments.
Las Vegas Sands (LVS) goes into business for Macau amid pandemic
According to the Zacks analyst, Las Vegas Sands’ planned investment in new investment projects in Macau will boost growth.
Hess (HES) relies on oil-rich discoveries off Guyana
World-class discoveries in Guyana’s offshore resources have improved Hess’ production prospects. However, the significant exposure to the upstream company debt relates to the Zacks analyst.
High margin assets and cost management help Devon Energy (DVN)
According to the Zacks analyst, Devon’s strong production from high-margin assets and efficient cost management will boost its long-term performance.
Real brand investments to shape Boston Beer (SAM) growth
According to the Zacks analyst, the Truly brand saw significant market share growth in the measured offsite channel in the first quarter, surpassing the hard salts category. The brand is expected to lead growth in 2021.
Ryder (R) Top Line Gains Traction With Freight Recovery
The Zacks analyst appreciates the company’s efforts to reward its shareholders. In addition, healthier conditions in the freight market are contributing to Ryder’s performance.
Improved markets and pricing actions for Aid Greif (GEF)
Zacks analyst believes Greif will benefit from improvements in several of its key markets. Pricing actions to tackle cost inflation and its ongoing restructuring activities will boost margins.
Interest rates close to zero, high costs Hurt Schwab (SCHW)
Zacks analyst says near zero interest rates are likely to continue to put pressure on Schwab’s margins, hurting sales. The persistent rise in spending could hamper earnings growth.
Inorganic growth aids, high costs hurt HCA Healthcare (HCA)
According to the Zacks analyst, a number of strategic acquisitions have strengthened its portfolio and increased its scale, resulting in overall growth. However, escalating spending remains a concern.
Rising First American Aid (FAF) rates, worrying rising costs
According to the Zacks analyst, First American is expected to grow thanks to the strength of the commercial business and the demand of millennials to buy a first home. However, rising costs and high debt levels are still there.
Click to get this free report
Shopify Inc. (SHOP): Free Inventory Analysis Report
Prologis, Inc. (PLD): Free Stock Analysis Report
Micron Technology, Inc. (MU): Free Stock Analysis Report
Ecolab Inc. (ECL): Free Stock Analysis Report
salesforce.com, inc. (CRM): Free stock analysis report
AstraZeneca PLC (AZN): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks investment research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.